Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados

Topics

Temas

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Figuras y tablas -
Figure 1

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Higher versus lower PUFA intake, Outcome 1 All allergic disease.
Figuras y tablas -
Analysis 1.1

Comparison 1 Higher versus lower PUFA intake, Outcome 1 All allergic disease.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Higher versus lower PUFA intake, Outcome 2 Asthma.
Figuras y tablas -
Analysis 1.2

Comparison 1 Higher versus lower PUFA intake, Outcome 2 Asthma.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Higher versus lower PUFA intake, Outcome 3 Dermatitis/eczema.
Figuras y tablas -
Analysis 1.3

Comparison 1 Higher versus lower PUFA intake, Outcome 3 Dermatitis/eczema.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Higher versus lower PUFA intake, Outcome 4 Allergic rhinitis.
Figuras y tablas -
Analysis 1.4

Comparison 1 Higher versus lower PUFA intake, Outcome 4 Allergic rhinitis.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Higher versus lower PUFA intake, Outcome 5 Food allergy.
Figuras y tablas -
Analysis 1.5

Comparison 1 Higher versus lower PUFA intake, Outcome 5 Food allergy.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 1 All allergic disease ‐ infant incidence.
Figuras y tablas -
Analysis 2.1

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 1 All allergic disease ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 2 All allergic disease ‐ childhood incidence.
Figuras y tablas -
Analysis 2.2

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 2 All allergic disease ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 3 All allergic disease ‐ childhood prevalence.
Figuras y tablas -
Analysis 2.3

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 3 All allergic disease ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 4 Asthma ‐ infant incidence.
Figuras y tablas -
Analysis 2.4

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 4 Asthma ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 5 Asthma ‐ childhood incidence.
Figuras y tablas -
Analysis 2.5

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 5 Asthma ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 6 Asthma ‐ childhood prevalence.
Figuras y tablas -
Analysis 2.6

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 6 Asthma ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 7 Dermatitis/eczema ‐ infant incidence.
Figuras y tablas -
Analysis 2.7

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 7 Dermatitis/eczema ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 8 Dermatitis/eczema ‐ childhood incidence.
Figuras y tablas -
Analysis 2.8

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 8 Dermatitis/eczema ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 9 Dermatitis/eczema ‐ childhood prevalence.
Figuras y tablas -
Analysis 2.9

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 9 Dermatitis/eczema ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 10 Allergic rhinitis ‐ infant incidence.
Figuras y tablas -
Analysis 2.10

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 10 Allergic rhinitis ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 11 Allergic rhinitis ‐ childhood prevalence.
Figuras y tablas -
Analysis 2.11

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 11 Allergic rhinitis ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 12 Food allergy ‐ infant incidence.
Figuras y tablas -
Analysis 2.12

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 12 Food allergy ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 13 Food allergy ‐ childhood incidence.
Figuras y tablas -
Analysis 2.13

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 13 Food allergy ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 14 Food allergy ‐ childhood prevalence.
Figuras y tablas -
Analysis 2.14

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 14 Food allergy ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 1 All allergic disease ‐ infant incidence.
Figuras y tablas -
Analysis 3.1

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 1 All allergic disease ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 2 All allergic disease ‐ childhood incidence.
Figuras y tablas -
Analysis 3.2

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 2 All allergic disease ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 3 All allergic disease ‐ childhood prevalence.
Figuras y tablas -
Analysis 3.3

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 3 All allergic disease ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 4 Asthma ‐ infant incidence.
Figuras y tablas -
Analysis 3.4

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 4 Asthma ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 5 Asthma ‐ childhood incidence.
Figuras y tablas -
Analysis 3.5

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 5 Asthma ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 6 Asthma ‐ childhood prevalence.
Figuras y tablas -
Analysis 3.6

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 6 Asthma ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 7 Dermatitis/eczema ‐ infant incidence.
Figuras y tablas -
Analysis 3.7

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 7 Dermatitis/eczema ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 8 Dermatitis/eczema ‐ childhood incidence.
Figuras y tablas -
Analysis 3.8

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 8 Dermatitis/eczema ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 9 Dermatitis/eczema ‐ childhood prevalence.
Figuras y tablas -
Analysis 3.9

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 9 Dermatitis/eczema ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 10 Allergic rhinitis ‐ infant incidence.
Figuras y tablas -
Analysis 3.10

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 10 Allergic rhinitis ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 11 Allergic rhinitis ‐ childhood prevalence.
Figuras y tablas -
Analysis 3.11

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 11 Allergic rhinitis ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 12 Food allergy ‐ infant incidence.
Figuras y tablas -
Analysis 3.12

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 12 Food allergy ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 13 Food allergy ‐ childhood incidence.
Figuras y tablas -
Analysis 3.13

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 13 Food allergy ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 14 Food allergy ‐ childhood prevalence.
Figuras y tablas -
Analysis 3.14

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 14 Food allergy ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 1 All allergic disease ‐ infant incidence.
Figuras y tablas -
Analysis 4.1

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 1 All allergic disease ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 2 All allergic disease ‐ childhood incidence.
Figuras y tablas -
Analysis 4.2

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 2 All allergic disease ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 3 All allergic disease ‐ childhood prevalence.
Figuras y tablas -
Analysis 4.3

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 3 All allergic disease ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 4 Asthma ‐ infant incidence.
Figuras y tablas -
Analysis 4.4

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 4 Asthma ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 5 Asthma ‐ childhood incidence.
Figuras y tablas -
Analysis 4.5

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 5 Asthma ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 6 Asthma ‐ childhood prevalence.
Figuras y tablas -
Analysis 4.6

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 6 Asthma ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 7 Dermatitis/eczema ‐ infant incidence.
Figuras y tablas -
Analysis 4.7

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 7 Dermatitis/eczema ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 8 Dermatitis/eczema ‐ childhood incidence.
Figuras y tablas -
Analysis 4.8

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 8 Dermatitis/eczema ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 9 Dermatitis/eczema ‐ childhood prevalence.
Figuras y tablas -
Analysis 4.9

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 9 Dermatitis/eczema ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 10 Allergic rhinitis ‐ infant incidence.
Figuras y tablas -
Analysis 4.10

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 10 Allergic rhinitis ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 11 Allergic rhinitis ‐ childhood prevalence.
Figuras y tablas -
Analysis 4.11

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 11 Allergic rhinitis ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 12 Food allergy ‐ infant incidence.
Figuras y tablas -
Analysis 4.12

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 12 Food allergy ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 13 Food allergy ‐ childhood incidence.
Figuras y tablas -
Analysis 4.13

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 13 Food allergy ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 14 Food allergy ‐ childhood prevalence.
Figuras y tablas -
Analysis 4.14

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 14 Food allergy ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 1 All allergic disease ‐ infant incidence.
Figuras y tablas -
Analysis 5.1

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 1 All allergic disease ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 2 All allergic disease ‐ childhood incidence.
Figuras y tablas -
Analysis 5.2

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 2 All allergic disease ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 3 All allergic disease ‐ childhood prevalence.
Figuras y tablas -
Analysis 5.3

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 3 All allergic disease ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 4 Asthma ‐ infant incidence.
Figuras y tablas -
Analysis 5.4

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 4 Asthma ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 5 Asthma ‐ childhood incidence.
Figuras y tablas -
Analysis 5.5

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 5 Asthma ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 6 Asthma ‐ childhood prevalence.
Figuras y tablas -
Analysis 5.6

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 6 Asthma ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 7 Dermatitis/eczema ‐ infant incidence.
Figuras y tablas -
Analysis 5.7

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 7 Dermatitis/eczema ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 8 Dermatitis/eczema ‐ childhood incidence.
Figuras y tablas -
Analysis 5.8

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 8 Dermatitis/eczema ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 9 Dermatitis/eczema ‐ childhood prevalence.
Figuras y tablas -
Analysis 5.9

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 9 Dermatitis/eczema ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 10 Allergic rhinitis ‐ infant incidence.
Figuras y tablas -
Analysis 5.10

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 10 Allergic rhinitis ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 11 Allergic rhinitis ‐ childhood prevalence.
Figuras y tablas -
Analysis 5.11

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 11 Allergic rhinitis ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 12 Food allergy ‐ infant incidence.
Figuras y tablas -
Analysis 5.12

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 12 Food allergy ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 13 Food allergy ‐ childhood incidence.
Figuras y tablas -
Analysis 5.13

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 13 Food allergy ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 14 Food allergy ‐ childhood prevalence.
Figuras y tablas -
Analysis 5.14

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 14 Food allergy ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 1 All allergic disease ‐ infant incidence.
Figuras y tablas -
Analysis 6.1

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 1 All allergic disease ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 2 All allergic disease ‐ childhood incidence.
Figuras y tablas -
Analysis 6.2

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 2 All allergic disease ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 3 All allergic disease ‐ childhood prevalence.
Figuras y tablas -
Analysis 6.3

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 3 All allergic disease ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 4 Asthma ‐ infant incidence.
Figuras y tablas -
Analysis 6.4

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 4 Asthma ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 5 Asthma ‐ childhood incidence.
Figuras y tablas -
Analysis 6.5

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 5 Asthma ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 6 Asthma ‐ childhood prevalence.
Figuras y tablas -
Analysis 6.6

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 6 Asthma ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 7 Dermatitis/eczema ‐ infant incidence.
Figuras y tablas -
Analysis 6.7

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 7 Dermatitis/eczema ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 8 Dermatitis/eczema ‐ childhood incidence.
Figuras y tablas -
Analysis 6.8

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 8 Dermatitis/eczema ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 9 Dermatitis/eczema ‐ childhood prevalence.
Figuras y tablas -
Analysis 6.9

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 9 Dermatitis/eczema ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 10 Allergic rhinitis ‐ infant incidence.
Figuras y tablas -
Analysis 6.10

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 10 Allergic rhinitis ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 11 Allergic rhinitis ‐ childhood prevalence.
Figuras y tablas -
Analysis 6.11

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 11 Allergic rhinitis ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 12 Food allergy ‐ infant incidence.
Figuras y tablas -
Analysis 6.12

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 12 Food allergy ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 13 Food allergy ‐ childhood incidence.
Figuras y tablas -
Analysis 6.13

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 13 Food allergy ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 14 Food allergy ‐ childhood prevalence.
Figuras y tablas -
Analysis 6.14

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 14 Food allergy ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 Higher versus lower PUFA intake: sensitivity analysis, Outcome 1 Asthma.
Figuras y tablas -
Analysis 7.1

Comparison 7 Higher versus lower PUFA intake: sensitivity analysis, Outcome 1 Asthma.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 Higher versus lower PUFA intake: sensitivity analysis, Outcome 2 Dermatitis/eczema.
Figuras y tablas -
Analysis 7.2

Comparison 7 Higher versus lower PUFA intake: sensitivity analysis, Outcome 2 Dermatitis/eczema.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 Higher versus lower PUFA intake: sensitivity analysis, Outcome 3 Allergic rhinitis.
Figuras y tablas -
Analysis 7.3

Comparison 7 Higher versus lower PUFA intake: sensitivity analysis, Outcome 3 Allergic rhinitis.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 Higher versus lower PUFA intake: sensitivity analysis, Outcome 4 Food allergy.
Figuras y tablas -
Analysis 7.4

Comparison 7 Higher versus lower PUFA intake: sensitivity analysis, Outcome 4 Food allergy.

Ir a la figura de la revisiónAbrir en una pestaña nueva
Summary of findings for the main comparison. Higher versus lower PUFA intake for the prevention of allergy ‐ infant incidence

Higher versus lower PUFA intake for the prevention of allergy ‐ infant incidence

Patient or population: infants
Settings: hospital or community
Intervention: higher versus lower PUFA intake

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Lower PUFA intake

Higher PUFA intake

All allergic disease ‐ infant incidence
Follow‐up: 1 years

Study population

RR 0.96
(0.73 to 1.26)

323
(1 study)

⊕⊝⊝⊝
very low1,2,3

‐

395 per 1000

379 per 1000
(289 to 498)

Moderate

395 per 1000

379 per 1000
(288 to 498)

Asthma ‐ infant incidence
Follow‐up: 2 years

Study population

RR 1.04
(0.8 to 1.35)

1162
(3 studies)

⊕⊕⊝⊝
low4,5

‐

160 per 1000

167 per 1000
(128 to 217)

Moderate

124 per 1000

129 per 1000
(99 to 167)

Dermatitis/eczema ‐ infant incidence
Follow‐up: 2 years

Study population

RR 0.93
(0.82 to 1.06)

1906
(7 studies)

⊕⊝⊝⊝
very low3,4,5

‐

326 per 1000

303 per 1000
(267 to 346)

Moderate

323 per 1000

300 per 1000
(265 to 342)

Allergic rhinitis ‐ infant incidence
Follow‐up: 2 years

Study population

RR 0.47
(0.23 to 0.96)

594
(2 studies)

⊕⊝⊝⊝
very low3,4,5,6

‐

74 per 1000

35 per 1000
(17 to 71)

Moderate

58 per 1000

27 per 1000
(13 to 56)

Food allergy ‐ infant incidence
Follow‐up: 2 years

Study population

RR 0.81
(0.56 to 1.19)

915
(3 studies)

⊕⊝⊝⊝
very low3,4,5,7

‐

118 per 1000

95 per 1000
(66 to 140)

Moderate

150 per 1000

121 per 1000
(84 to 179)

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; PUFA: polyunsaturated fatty acid; RR: risk ratio.

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1 Losses to follow‐up
2 Reported by single study only.
3 Wide confidence intervals.
4 Single high quality study.
5 Reported by a minority of studies.
6 Single study reported an effect.
7 Substantial heterogeneity.

Figuras y tablas -
Summary of findings for the main comparison. Higher versus lower PUFA intake for the prevention of allergy ‐ infant incidence
Ir a la tabla de la revisión
Summary of findings 2. Higher versus lower PUFA intake for the prevention of allergy ‐ childhood incidence

Higher versus lower PUFA intake for the prevention of allergy ‐ childhood incidence

Patient or population: infants
Settings: hospital or community
Intervention: higher versus lower PUFA intake

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Lower PUFA intake

Higher PUFA intake

All allergic disease ‐ childhood incidence
Follow‐up: 3 years

Study population

RR 0.69
(0.47 to 1.02)

154
(2 studies)

⊕⊝⊝⊝
very low1,2,3,4

‐

519 per 1000

358 per 1000
(244 to 529)

Moderate

483 per 1000

333 per 1000
(227 to 493)

Asthma ‐ childhood incidence
Follow‐up: 3 years

Study population

RR 0.45
(0.2 to 1.02)

89
(1 study)

⊕⊝⊝⊝
very low1,3,5

‐

353 per 1000

159 per 1000
(71 to 360)

Moderate

353 per 1000

159 per 1000
(71 to 360)

Dermatitis/eczema ‐ childhood incidence
Follow‐up: 3 years

Study population

RR 0.65
(0.34 to 1.24)

154
(2 studies)

⊕⊝⊝⊝
very low1,3,4

‐

266 per 1000

173 per 1000
(90 to 330)

Moderate

238 per 1000

155 per 1000
(81 to 295)

Food allergy ‐ childhood incidence
Follow‐up: 3 years

Study population

RR 2.27
(0.25 to 20.68)

65
(1 study)

⊕⊝⊝⊝
very low1,3,5

‐

36 per 1000

81 per 1000
(9 to 739)

Moderate

36 per 1000

82 per 1000
(9 to 744)

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; PUFA: polyunsaturated fatty acid; RR: risk ratio.

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1 Very high losses to follow‐up.
2 Moderate heterogeneity.
3 Wide confidence intervals.
4 Minority of studies reported outcome.
5 Reported by single study.

Figuras y tablas -
Summary of findings 2. Higher versus lower PUFA intake for the prevention of allergy ‐ childhood incidence
Ir a la tabla de la revisión
Summary of findings 3. Higher versus lower PUFA intake for the prevention of allergy ‐ Childhood prevalence

Higher versus lower PUFA intake for the prevention of allergy ‐ childhood prevalence

Patient or population: infants
Settings: hospital or community
Intervention: higher versus lower PUFA intake

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Lower PUFA intake

Higher PUFA intake

All allergic disease ‐ childhood prevalence
Follow‐up: 3 years

Study population

RR 0.98
(0.81 to 1.19)

633
(2 studies)

⊕⊝⊝⊝
very low1,2,3

‐

394 per 1000

386 per 1000
(319 to 469)

Moderate

372 per 1000

365 per 1000
(301 to 443)

Asthma ‐ childhood prevalence
Follow‐up: 3 years

Study population

RR 1.12
(0.82 to 1.53)

635
(2 studies)

⊕⊝⊝⊝
very low1,3,4,5

‐

188 per 1000

210 per 1000
(154 to 287)

Moderate

164 per 1000

184 per 1000
(134 to 251)

Dermatitis/eczema ‐ childhood prevalence
Follow‐up: 3 years

Study population

RR 0.81
(0.59 to 1.09)

635
(2 studies)

⊕⊝⊝⊝
very low1,2,3

‐

229 per 1000

186 per 1000
(135 to 250)

Moderate

219 per 1000

177 per 1000
(129 to 239)

Allergic rhinitis ‐ childhood prevalence
Follow‐up: 3 years

Study population

RR 1.02
(0.83 to 1.25)

635
(2 studies)

⊕⊝⊝⊝
very low1,2,3

‐

331 per 1000

338 per 1000
(275 to 414)

Moderate

220 per 1000

224 per 1000
(183 to 275)

Food allergy ‐ childhood prevalence
Follow‐up: 3 years

Study population

RR 0.27
(0.06 to 1.19)

119
(1 study)

⊕⊝⊝⊝
very low2,4

‐

138 per 1000

37 per 1000
(8 to 165)

Moderate

139 per 1000

38 per 1000
(8 to 165)

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; PUFA: polyunsaturated fatty acid; RR: risk ratio.

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1 Losses to follow‐up > 10%.
2 Wide confidence intervals.
3 Reported by a minority of studies.
4 Reported by single study.
5 Very high losses to follow‐up.

Figuras y tablas -
Summary of findings 3. Higher versus lower PUFA intake for the prevention of allergy ‐ Childhood prevalence
Ir a la tabla de la revisión
Comparison 1. Higher versus lower PUFA intake

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 All allergic disease Show forest plot

5

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

1.1 Infant incidence

1

323

Risk Ratio (M‐H, Fixed, 95% CI)

0.96 [0.73, 1.26]

1.2 Childhood incidence

2

154

Risk Ratio (M‐H, Fixed, 95% CI)

0.69 [0.47, 1.02]

1.3 Childhood prevalence

2

633

Risk Ratio (M‐H, Fixed, 95% CI)

0.98 [0.81, 1.19]

2 Asthma Show forest plot

4

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 Infant incidence

3

1162

Risk Ratio (M‐H, Fixed, 95% CI)

1.04 [0.80, 1.35]

2.2 Childhood incidence

1

89

Risk Ratio (M‐H, Fixed, 95% CI)

0.45 [0.20, 1.02]

2.3 Childhood prevalence

2

635

Risk Ratio (M‐H, Fixed, 95% CI)

1.12 [0.82, 1.53]

3 Dermatitis/eczema Show forest plot

9

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

3.1 Infant incidence

7

1906

Risk Ratio (M‐H, Fixed, 95% CI)

0.93 [0.82, 1.06]

3.2 Childhood incidence

2

154

Risk Ratio (M‐H, Fixed, 95% CI)

0.65 [0.34, 1.24]

3.3 Childhood prevalence

2

635

Risk Ratio (M‐H, Fixed, 95% CI)

0.81 [0.59, 1.09]

4 Allergic rhinitis Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

4.1 Infant incidence

2

594

Risk Ratio (M‐H, Fixed, 95% CI)

0.47 [0.23, 0.96]

4.2 Childhood prevalence

2

635

Risk Ratio (M‐H, Fixed, 95% CI)

1.02 [0.83, 1.25]

5 Food allergy Show forest plot

4

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

5.1 Infant incidence

3

915

Risk Ratio (M‐H, Fixed, 95% CI)

0.81 [0.56, 1.19]

5.2 Childhood incidence

1

65

Risk Ratio (M‐H, Fixed, 95% CI)

2.27 [0.25, 20.68]

5.3 Childhood prevalence

1

119

Risk Ratio (M‐H, Fixed, 95% CI)

0.27 [0.06, 1.19]
Figuras y tablas -
Comparison 1. Higher versus lower PUFA intake
Ir a la tabla de la revisión
Comparison 2. Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 All allergic disease ‐ infant incidence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

1.1 Infant supplementation

1

323

Risk Ratio (M‐H, Fixed, 95% CI)

0.96 [0.73, 1.26]

2 All allergic disease ‐ childhood incidence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 Infant supplementation

1

89

Risk Ratio (M‐H, Fixed, 95% CI)

0.56 [0.34, 0.92]

2.2 Maternal supplementation

1

65

Risk Ratio (M‐H, Fixed, 95% CI)

0.98 [0.51, 1.91]

3 All allergic disease ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

3.1 Infant supplementation

1

516

Risk Ratio (M‐H, Fixed, 95% CI)

1.01 [0.83, 1.25]

3.2 Maternal supplementation

1

117

Risk Ratio (M‐H, Fixed, 95% CI)

0.78 [0.44, 1.38]

4 Asthma ‐ infant incidence Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

4.1 Infant supplementation

1

554

Risk Ratio (M‐H, Fixed, 95% CI)

1.19 [0.78, 1.81]

4.2 Maternal supplementation

2

608

Risk Ratio (M‐H, Fixed, 95% CI)

0.96 [0.69, 1.33]

5 Asthma ‐ childhood incidence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

5.1 Infant supplementation

1

89

Risk Ratio (M‐H, Fixed, 95% CI)

0.45 [0.20, 1.02]

6 Asthma ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

6.1 Infant supplementation

1

516

Risk Ratio (M‐H, Fixed, 95% CI)

1.13 [0.82, 1.57]

6.2 Maternal supplementation

1

119

Risk Ratio (M‐H, Fixed, 95% CI)

1.05 [0.41, 2.72]

7 Dermatitis/eczema ‐ infant incidence Show forest plot

7

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

7.1 Infant supplementation

5

1245

Risk Ratio (M‐H, Fixed, 95% CI)

0.95 [0.82, 1.11]

7.2 Maternal supplementation

3

661

Risk Ratio (M‐H, Fixed, 95% CI)

0.88 [0.68, 1.15]

8 Dermatitis/eczema ‐ childhood incidence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

8.1 Infant supplementation

1

89

Risk Ratio (M‐H, Fixed, 95% CI)

0.55 [0.25, 1.20]

8.2 Maternal supplementation

1

65

Risk Ratio (M‐H, Fixed, 95% CI)

0.95 [0.28, 3.20]

9 Dermatitis/eczema ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

9.1 Infant supplementation

1

516

Risk Ratio (M‐H, Fixed, 95% CI)

0.85 [0.62, 1.18]

9.2 Maternal supplementation

1

119

Risk Ratio (M‐H, Fixed, 95% CI)

0.56 [0.23, 1.36]

10 Allergic rhinitis ‐ infant incidence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

10.1 Maternal supplementation

2

594

Risk Ratio (M‐H, Fixed, 95% CI)

0.47 [0.23, 0.96]

11 Allergic rhinitis ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

11.1 Infant supplementation

1

516

Risk Ratio (M‐H, Fixed, 95% CI)

1.01 [0.83, 1.25]

11.2 Maternal supplementation

1

119

Risk Ratio (M‐H, Fixed, 95% CI)

1.20 [0.18, 8.26]

12 Food allergy ‐ infant incidence Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

12.1 Infant supplementation

1

323

Risk Ratio (M‐H, Fixed, 95% CI)

0.81 [0.47, 1.42]

12.2 Maternal supplementation

2

592

Risk Ratio (M‐H, Fixed, 95% CI)

0.81 [0.48, 1.37]

13 Food allergy ‐ childhood incidence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

13.1 Maternal supplementation

1

65

Risk Ratio (M‐H, Fixed, 95% CI)

2.27 [0.25, 20.68]

14 Food allergy ‐ childhood prevalence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

14.1 Maternal supplementation

1

119

Risk Ratio (M‐H, Fixed, 95% CI)

0.27 [0.06, 1.19]
Figuras y tablas -
Comparison 2. Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother
Ir a la tabla de la revisión
Comparison 3. Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 All allergic disease ‐ infant incidence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

1.1 n‐3 supplementation

1

323

Risk Ratio (M‐H, Fixed, 95% CI)

0.96 [0.73, 1.26]

2 All allergic disease ‐ childhood incidence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 n‐3 supplementation

2

154

Risk Ratio (M‐H, Fixed, 95% CI)

0.69 [0.47, 1.02]

3 All allergic disease ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

3.1 n‐3 supplementation

2

633

Risk Ratio (M‐H, Fixed, 95% CI)

0.98 [0.81, 1.19]

4 Asthma ‐ infant incidence Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

4.1 n‐3 supplementation

3

1162

Risk Ratio (M‐H, Fixed, 95% CI)

1.04 [0.80, 1.35]

5 Asthma ‐ childhood incidence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

5.1 n‐3 supplementation

1

89

Risk Ratio (M‐H, Fixed, 95% CI)

0.45 [0.20, 1.02]

6 Asthma ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

6.1 n‐3 supplementation

2

635

Risk Ratio (M‐H, Fixed, 95% CI)

1.12 [0.82, 1.53]

7 Dermatitis/eczema ‐ infant incidence Show forest plot

7

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

7.1 n‐3 supplementation

5

1657

Risk Ratio (M‐H, Fixed, 95% CI)

0.95 [0.82, 1.09]

7.2 n‐6 supplementation

2

249

Risk Ratio (M‐H, Fixed, 95% CI)

0.85 [0.59, 1.23]

8 Dermatitis/eczema ‐ childhood incidence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

8.1 n‐3 supplementation

2

154

Risk Ratio (M‐H, Fixed, 95% CI)

0.65 [0.34, 1.24]

9 Dermatitis/eczema ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

9.1 n‐3 supplementation

2

635

Risk Ratio (M‐H, Fixed, 95% CI)

0.81 [0.59, 1.09]

10 Allergic rhinitis ‐ infant incidence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

10.1 n‐3 supplementation

2

594

Risk Ratio (M‐H, Fixed, 95% CI)

0.47 [0.23, 0.96]

11 Allergic rhinitis ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

11.1 n‐3 supplementation

2

635

Risk Ratio (M‐H, Fixed, 95% CI)

1.02 [0.83, 1.25]

12 Food allergy ‐ infant incidence Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

12.1 n‐3 supplementation

3

915

Risk Ratio (M‐H, Fixed, 95% CI)

0.81 [0.56, 1.19]

13 Food allergy ‐ childhood incidence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

13.1 n‐3 supplementation

1

65

Risk Ratio (M‐H, Fixed, 95% CI)

2.27 [0.25, 20.68]

14 Food allergy ‐ childhood prevalence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

14.1 n‐3 supplementation

1

119

Risk Ratio (M‐H, Fixed, 95% CI)

0.27 [0.06, 1.19]
Figuras y tablas -
Comparison 3. Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation
Ir a la tabla de la revisión
Comparison 4. Higher versus lower PUFA intake: subgrouped by method of infant feeding

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 All allergic disease ‐ infant incidence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

1.1 Human milk fed infants

1

323

Risk Ratio (M‐H, Fixed, 95% CI)

0.96 [0.73, 1.26]

2 All allergic disease ‐ childhood incidence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 Human milk fed infants

1

65

Risk Ratio (M‐H, Fixed, 95% CI)

0.98 [0.51, 1.91]

2.2 Formula fed infants

1

89

Risk Ratio (M‐H, Fixed, 95% CI)

0.56 [0.34, 0.92]

3 All allergic disease ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

3.1 Human milk fed infants

2

633

Risk Ratio (M‐H, Fixed, 95% CI)

0.98 [0.81, 1.19]

4 Asthma ‐ infant incidence Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

5 Asthma ‐ childhood incidence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

5.1 Formula fed infants

1

89

Risk Ratio (M‐H, Fixed, 95% CI)

0.45 [0.20, 1.02]

6 Asthma ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

6.1 Human milk fed infants

2

635

Risk Ratio (M‐H, Fixed, 95% CI)

1.12 [0.82, 1.53]

7 Dermatitis/eczema ‐ infant incidence Show forest plot

7

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

7.1 Human milk fed infants

6

1715

Risk Ratio (M‐H, Fixed, 95% CI)

0.95 [0.82, 1.09]

7.2 Formula fed infants

2

191

Risk Ratio (M‐H, Fixed, 95% CI)

0.84 [0.57, 1.23]

8 Dermatitis/eczema ‐ childhood incidence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

8.1 Human milk fed infants

1

65

Risk Ratio (M‐H, Fixed, 95% CI)

0.95 [0.28, 3.20]

8.2 Formula fed infants

1

89

Risk Ratio (M‐H, Fixed, 95% CI)

0.55 [0.25, 1.20]

9 Dermatitis/eczema ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

9.1 Human milk fed infants

2

635

Risk Ratio (M‐H, Fixed, 95% CI)

0.81 [0.59, 1.09]

10 Allergic rhinitis ‐ infant incidence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

10.1 Human milk fed infants

2

594

Risk Ratio (M‐H, Fixed, 95% CI)

0.47 [0.23, 0.96]

11 Allergic rhinitis ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

11.1 Human milk fed infants

2

635

Risk Ratio (M‐H, Fixed, 95% CI)

1.02 [0.83, 1.25]

12 Food allergy ‐ infant incidence Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

12.1 Human milk fed infants

3

915

Risk Ratio (M‐H, Fixed, 95% CI)

0.81 [0.56, 1.19]

13 Food allergy ‐ childhood incidence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

13.1 Human milk fed infants

1

65

Risk Ratio (M‐H, Fixed, 95% CI)

2.27 [0.25, 20.68]

14 Food allergy ‐ childhood prevalence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

14.1 Human milk fed infants

1

119

Risk Ratio (M‐H, Fixed, 95% CI)

0.27 [0.06, 1.19]
Figuras y tablas -
Comparison 4. Higher versus lower PUFA intake: subgrouped by method of infant feeding
Ir a la tabla de la revisión
Comparison 5. Higher versus lower PUFA intake: subgrouped by infant heredity for allergy

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 All allergic disease ‐ infant incidence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

1.1 High risk for allergy

1

323

Risk Ratio (M‐H, Fixed, 95% CI)

0.96 [0.73, 1.26]

2 All allergic disease ‐ childhood incidence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 Risk for allergy not selected

2

154

Risk Ratio (M‐H, Fixed, 95% CI)

0.69 [0.47, 1.02]

3 All allergic disease ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

3.1 High risk for allergy

2

633

Risk Ratio (M‐H, Fixed, 95% CI)

0.98 [0.81, 1.19]

4 Asthma ‐ infant incidence Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

4.1 High risk for allergy

2

673

Risk Ratio (M‐H, Fixed, 95% CI)

1.16 [0.79, 1.71]

4.2 Risk for allergy not selected

1

489

Risk Ratio (M‐H, Fixed, 95% CI)

0.94 [0.66, 1.34]

5 Asthma ‐ childhood incidence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

5.1 Risk for allergy not selected

1

89

Risk Ratio (M‐H, Fixed, 95% CI)

0.45 [0.20, 1.02]

6 Asthma ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

6.1 High risk for allergy

2

635

Risk Ratio (M‐H, Fixed, 95% CI)

1.12 [0.82, 1.53]

7 Dermatitis/eczema ‐ infant incidence Show forest plot

7

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

7.1 High risk for allergy

5

1245

Risk Ratio (M‐H, Fixed, 95% CI)

0.96 [0.81, 1.12]

7.2 Risk for allergy not selected

2

661

Risk Ratio (M‐H, Fixed, 95% CI)

0.89 [0.71, 1.12]

8 Dermatitis/eczema ‐ childhood incidence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

8.1 Risk for allergy not selected

2

154

Risk Ratio (M‐H, Fixed, 95% CI)

0.65 [0.34, 1.24]

9 Dermatitis/eczema ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

9.1 High risk for allergy

2

635

Risk Ratio (M‐H, Fixed, 95% CI)

0.81 [0.59, 1.09]

10 Allergic rhinitis ‐ infant incidence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

10.1 High risk for allergy

1

119

Risk Ratio (M‐H, Fixed, 95% CI)

1.20 [0.18, 8.26]

10.2 Risk for allergy not selected

1

475

Risk Ratio (M‐H, Fixed, 95% CI)

0.40 [0.18, 0.89]

11 Allergic rhinitis ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

11.1 High risk for allergy

2

635

Risk Ratio (M‐H, Fixed, 95% CI)

1.02 [0.83, 1.25]

12 Food allergy ‐ infant incidence Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

12.1 High risk for allergy

2

442

Risk Ratio (M‐H, Fixed, 95% CI)

0.62 [0.38, 1.02]

12.2 Risk for allergy not selected

1

473

Risk Ratio (M‐H, Fixed, 95% CI)

1.24 [0.67, 2.31]

13 Food allergy ‐ childhood incidence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

13.1 Risk for allergy not selected

1

65

Risk Ratio (M‐H, Fixed, 95% CI)

2.27 [0.25, 20.68]

14 Food allergy ‐ childhood prevalence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

14.1 High risk for allergy

1

119

Risk Ratio (M‐H, Fixed, 95% CI)

0.27 [0.06, 1.19]
Figuras y tablas -
Comparison 5. Higher versus lower PUFA intake: subgrouped by infant heredity for allergy
Ir a la tabla de la revisión
Comparison 6. Higher versus lower PUFA intake: subgrouped by gestational age at birth

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 All allergic disease ‐ infant incidence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

1.1 Term infants

1

323

Risk Ratio (M‐H, Fixed, 95% CI)

0.96 [0.73, 1.26]

2 All allergic disease ‐ childhood incidence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 Term infants

2

154

Risk Ratio (M‐H, Fixed, 95% CI)

0.69 [0.47, 1.02]

3 All allergic disease ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

3.1 Term infants

2

633

Risk Ratio (M‐H, Fixed, 95% CI)

0.98 [0.81, 1.19]

4 Asthma ‐ infant incidence Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

4.1 Term infants

2

673

Risk Ratio (M‐H, Fixed, 95% CI)

1.16 [0.79, 1.71]

4.2 Preterm infants

1

489

Risk Ratio (M‐H, Fixed, 95% CI)

0.94 [0.66, 1.34]

5 Asthma ‐ childhood incidence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

5.1 Term infants

1

89

Risk Ratio (M‐H, Fixed, 95% CI)

0.45 [0.20, 1.02]

6 Asthma ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

6.1 Term infants

2

635

Risk Ratio (M‐H, Fixed, 95% CI)

1.12 [0.82, 1.53]

7 Dermatitis/eczema ‐ infant incidence Show forest plot

7

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

7.1 Term infants

6

1422

Risk Ratio (M‐H, Fixed, 95% CI)

0.93 [0.80, 1.07]

7.2 Preterm infants

1

484

Risk Ratio (M‐H, Fixed, 95% CI)

0.96 [0.71, 1.29]

8 Dermatitis/eczema ‐ childhood incidence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

8.1 Term infants

2

154

Risk Ratio (M‐H, Fixed, 95% CI)

0.65 [0.34, 1.24]

9 Dermatitis/eczema ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

9.1 Term infants

2

635

Risk Ratio (M‐H, Fixed, 95% CI)

0.81 [0.59, 1.09]

10 Allergic rhinitis ‐ infant incidence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

10.1 Term infants

1

119

Risk Ratio (M‐H, Fixed, 95% CI)

1.20 [0.18, 8.26]

10.2 Preterm infants

1

475

Risk Ratio (M‐H, Fixed, 95% CI)

0.40 [0.18, 0.89]

11 Allergic rhinitis ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

11.1 Term infants

2

635

Risk Ratio (M‐H, Fixed, 95% CI)

1.02 [0.83, 1.25]

12 Food allergy ‐ infant incidence Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

12.1 Term infants

2

442

Risk Ratio (M‐H, Fixed, 95% CI)

0.62 [0.38, 1.02]

12.2 Preterm infants

1

473

Risk Ratio (M‐H, Fixed, 95% CI)

1.24 [0.67, 2.31]

13 Food allergy ‐ childhood incidence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

13.1 Term infants

1

65

Risk Ratio (M‐H, Fixed, 95% CI)

2.27 [0.25, 20.68]

14 Food allergy ‐ childhood prevalence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

14.1 Term infants

1

119

Risk Ratio (M‐H, Fixed, 95% CI)

0.27 [0.06, 1.19]
Figuras y tablas -
Comparison 6. Higher versus lower PUFA intake: subgrouped by gestational age at birth
Ir a la tabla de la revisión
Comparison 7. Higher versus lower PUFA intake: sensitivity analysis

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Asthma Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

1.1 Infant incidence

1

489

Risk Ratio (M‐H, Fixed, 95% CI)

0.94 [0.66, 1.34]

2 Dermatitis/eczema Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 Infant incidence

1

484

Risk Ratio (M‐H, Fixed, 95% CI)

0.96 [0.71, 1.29]

3 Allergic rhinitis Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

3.1 Infant incidence

1

475

Risk Ratio (M‐H, Fixed, 95% CI)

0.40 [0.18, 0.89]

4 Food allergy Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

4.1 Infant incidence

1

473

Risk Ratio (M‐H, Fixed, 95% CI)

1.24 [0.67, 2.31]
Figuras y tablas -
Comparison 7. Higher versus lower PUFA intake: sensitivity analysis
Ir a la tabla de la revisión